Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AIM ImmunoTech (AIM) Receivables (2018 - 2023)

Historic Receivables for ImmunoTech (AIM) over the last 4 years, with Q4 2023 value amounting to $1.2 million.

  • ImmunoTech's Receivables changed N/A to $1.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was $1.2 million, marking a year-over-year change of. This contributed to the annual value of $1.2 million for FY2023, which is N/A changed from last year.
  • Latest data reveals that ImmunoTech reported Receivables of $1.2 million as of Q4 2023.
  • In the past 5 years, ImmunoTech's Receivables registered a high of $1.8 million during Q1 2023, and its lowest value of $26000.0 during Q3 2020.
  • In the last 3 years, ImmunoTech's Receivables had a median value of $76000.0 in 2019 and averaged $452818.2.
  • The largest annual percentage gain for ImmunoTech's Receivables in the last 5 years was 71386.14% (2020), contrasted with its biggest fall of 5806.45% (2020).
  • Quarter analysis of 3 years shows ImmunoTech's Receivables stood at $820000.0 in 2019, then tumbled by 96.83% to $26000.0 in 2020, then soared by 4453.85% to $1.2 million in 2023.
  • Its Receivables stands at $1.2 million for Q4 2023, versus $48000.0 for Q3 2023 and $33000.0 for Q2 2023.